Preoperative chemotherapy with Gemcitabine for pancreatic cancer causes zinc deficiency.

IF 1.7 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Pancreas Pub Date : 2024-08-06 DOI:10.1097/MPA.0000000000002396

Masahiro Iseki, Masamichi Mizuma, Mitsuhiro Shimura, Takashi Kokumai, Hideaki Sato, Akiko Kusaka, Shuichi Aoki, Koetsu Inoue, Shun Nakayama, Daisuke Douchi, Takayuki Miura, Shimpei Maeda, Masaharu Ishida, Kei Nakagawa, Takashi Kamei, Michiaki Unno

{"title":"Preoperative chemotherapy with Gemcitabine for pancreatic cancer causes zinc deficiency.","authors":"Masahiro Iseki, Masamichi Mizuma, Mitsuhiro Shimura, Takashi Kokumai, Hideaki Sato, Akiko Kusaka, Shuichi Aoki, Koetsu Inoue, Shun Nakayama, Daisuke Douchi, Takayuki Miura, Shimpei Maeda, Masaharu Ishida, Kei Nakagawa, Takashi Kamei, Michiaki Unno","doi":"10.1097/MPA.0000000000002396","DOIUrl":null,"url":null,"abstract":"Objectives: The aim of this study was to investigate how preoperative chemotherapy affected the serum zinc concentrations in patients with pancreatic cancer (PC).Methods: Two hundreds and thirty-one patients with PC who underwent pancreatectomy at our department from 2013 to 2019 were enrolled in this study and measured for the serum zinc concentrations before pancreatectomy. Patient characteristics, course of treatment, and laboratory data were analyzed.Results: One hundred thirty-five patients underwent upfront pancreatectomy and 58 received preoperative Gemcitabine + S1 (GEM + S1) and 29 received Gemcitabine + nab-Paclitaxel (GEM + nab-PTX). Comparing the serum zinc concentrations before and after preoperative treatment, it was found to decrease after treatment with statistical difference (79.3 μg/dl vs. 68.7 μg/dl, p < 0.001). The result was consistent with the investigation for both the patients who received GEM + S1 and those who received GEM + nab-PTX (p = 0.019, p < 0.001, respectively).Conclusions: The preoperative chemotherapy consistently reduced the serum zinc concentrations in the PC patients, regardless of their regimen such as GEM + S1 and GEM + nab-PTX. Monitoring the serum zinc concentration and appropriate zinc supplementation may be essential for PC patients undergoing preoperative chemotherapy and pancreatectomy.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPA.0000000000002396","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The aim of this study was to investigate how preoperative chemotherapy affected the serum zinc concentrations in patients with pancreatic cancer (PC).

Methods: Two hundreds and thirty-one patients with PC who underwent pancreatectomy at our department from 2013 to 2019 were enrolled in this study and measured for the serum zinc concentrations before pancreatectomy. Patient characteristics, course of treatment, and laboratory data were analyzed.

Results: One hundred thirty-five patients underwent upfront pancreatectomy and 58 received preoperative Gemcitabine + S1 (GEM + S1) and 29 received Gemcitabine + nab-Paclitaxel (GEM + nab-PTX). Comparing the serum zinc concentrations before and after preoperative treatment, it was found to decrease after treatment with statistical difference (79.3 μg/dl vs. 68.7 μg/dl, p < 0.001). The result was consistent with the investigation for both the patients who received GEM + S1 and those who received GEM + nab-PTX (p = 0.019, p < 0.001, respectively).

Conclusions: The preoperative chemotherapy consistently reduced the serum zinc concentrations in the PC patients, regardless of their regimen such as GEM + S1 and GEM + nab-PTX. Monitoring the serum zinc concentration and appropriate zinc supplementation may be essential for PC patients undergoing preoperative chemotherapy and pancreatectomy.

查看原文本刊更多论文

使用吉西他滨进行胰腺癌术前化疗会导致锌缺乏。

研究目的本研究旨在探讨术前化疗对胰腺癌（PC）患者血清锌浓度的影响：2013年至2019年在我科接受胰腺切除术的2 311例PC患者被纳入本研究，并在胰腺切除术前测定血清锌浓度。对患者特征、治疗过程和实验室数据进行了分析：135名患者接受了前期胰腺切除术，其中58名患者术前接受了吉西他滨+S1（GEM+S1）治疗，29名患者接受了吉西他滨+nab-紫杉醇（GEM+nab-PTX）治疗。比较术前治疗前后的血清锌浓度，发现治疗后血清锌浓度下降，且有统计学差异（79.3 μg/dl vs. 68.7 μg/dl，p < 0.001）。接受 GEM + S1 和 GEM + nab-PTX 治疗的患者的结果与调查结果显示一致（分别为 p = 0.019 和 p <0.001）：结论：无论采用GEM + S1还是GEM + nab-PTX方案，术前化疗都会持续降低PC患者的血清锌浓度。对于接受术前化疗和胰腺切除术的 PC 患者来说，监测血清锌浓度和适当补锌可能至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pancreas 医学-胃肠肝病学

CiteScore

4.70

自引率

3.40%

发文量

289

审稿时长

1 months

期刊介绍： Pancreas provides a central forum for communication of original works involving both basic and clinical research on the exocrine and endocrine pancreas and their interrelationships and consequences in disease states. This multidisciplinary, international journal covers the whole spectrum of basic sciences, etiology, prevention, pathophysiology, diagnosis, and surgical and medical management of pancreatic diseases, including cancer.